Intellia Therapeutics, Inc. (NTLA) Financials

NTLA Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 1.3 billion 250.8 million
2023-09-30 1.2 billion 205.9 million
2023-06-30 1.3 billion 218.4 million
2023-03-31 1.4 billion 227.0 million

NTLA Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -94.6 million 35.0 million
2023-09-30 -105.7 million 35.4 million
2023-06-30 -94.6 million 36.4 million
2023-03-31 -113.2 million 27.3 million

NTLA Net Income

No data available :(

NTLA Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 912.2 million - 115.3 million
2023-09-30 992.5 million - 118.3 million
2023-06-30 1.1 billion - 122.3 million
2023-03-31 1.2 billion - 126.1 million

NTLA Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 88.8 million
2023-09-30 88.6 million
2023-06-30 88.2 million
2023-03-31 87.8 million

NTLA Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1.5 million 109.0 million 29.0 million -
2023-09-30 4.3 million 113.7 million 29.4 million -
2023-06-30 4.3 million 115.3 million 30.7 million -
2023-03-31 3.8 million 97.1 million 27.4 million -

NTLA Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 -1.9 million 2.5 million
2023-09-30 12.0 million 2.3 million
2023-06-30 13.6 million 2.2 million
2023-03-31 12.6 million 2.0 million

NTLA

Price: $22.28

52 week price:
20.02
47.48

Earnings Per Share: -5.42 USD

P/E Ratio: -5.29

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 1.1 million

Ebitda: -15.1 million

Market Capitalization: 2.4 billion

Links: